Dravet syndrome
Conditions
Brief summary
Percent change from baseline in major motor seizure frequency (number per 28 days) in patients receiving zorevunersen as compared with sham from Week 16 to Week 28.
Detailed description
Percent change from baseline in major motor seizure frequency (number per 28 days) in patients receiving zorevunersen as compared with sham from Week 16 to Week 52., Change from baseline on a multi-component Vineland-3 Outcome Score in patients receiving zorevunersen as compared with sham at Week 52., Change from baseline in subdomain scores on the Vineland-3 in patients receiving zorevunersen as compared with sham at Week 52.
Interventions
DRUGSTK-001
Sponsors
Stoke Therapeutics Inc.
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change from baseline in major motor seizure frequency (number per 28 days) in patients receiving zorevunersen as compared with sham from Week 16 to Week 28. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent change from baseline in major motor seizure frequency (number per 28 days) in patients receiving zorevunersen as compared with sham from Week 16 to Week 52., Change from baseline on a multi-component Vineland-3 Outcome Score in patients receiving zorevunersen as compared with sham at Week 52., Change from baseline in subdomain scores on the Vineland-3 in patients receiving zorevunersen as compared with sham at Week 52. | — |
Countries
France, Germany, Italy, Poland, Spain, Sweden
Outcome results
None listed